Glimepiride

Physical Activity, Type 2 Diabetes, Diet + 4 more
Treatment
8 FDA approvals
20 Active Studies for Glimepiride

What is Glimepiride

GlimepirideThe Generic name of this drug
Treatment SummaryGlimepiride is a medication used to treat type 2 diabetes. It belongs to a class of drugs called sulfonylureas, which help lower blood sugar levels by stimulating the release of insulin from the pancreas. Glimepiride has a longer duration of action than other similar drugs and is associated with a lower risk of developing hypoglycemia and weight gain. It is effective in reducing fasting plasma glucose, postprandial glucose, and glycosylated hemoglobin levels. Glimepiride was approved by the FDA in 1995 and is typically taken once daily in pill form. It is sold under the brand
Amarylis the brand name
image of different drug pills on a surface
Glimepiride Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Amaryl
Glimepiride
2000
269

Approved as Treatment by the FDA

Glimepiride, otherwise known as Amaryl, is approved by the FDA for 8 uses which include Type 2 Diabetes Mellitus and Physical Activity .
Type 2 Diabetes Mellitus
Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone
Physical Activity
Used to treat Exercise in combination with Pioglitazone
Diet
Used to treat Diet in combination with Pioglitazone
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone
inadequate response to monotherapy
Used to treat inadequate response to monotherapy in combination with Pioglitazone
Inadequate Glycaemic Control
Used in combination with Insulin glargine to help manage Inadequate Glycaemic Control
Sulfonylurea Compounds
Used to treat prior thiazolidinedione and sulfonylurea treatment in combination with Pioglitazone
Inadequate Glucose Control
Used to treat Inadequate Glucose Control in combination with Metformin

Effectiveness

How Glimepiride Affects PatientsGlimepiride helps the body respond better to insulin and use glucose from the blood. In studies, patients taking glimepiride had a lower fasting plasma glucose, post-prandial glucose, and HbA1c than those taking a placebo. The 4- and 8-mg doses of glimepiride had the most significant effects, but the 4-mg dose was the most effective.
How Glimepiride works in the bodyGlimepiride works by blocking potassium channels in the pancreas that control insulin secretion. These channels open when the cell has a low ratio of ATP to ADP, which causes the cell to release potassium and become more negative. This inhibits insulin secretion. When the cell has a high ratio of ATP to ADP, the channels close and the cell becomes more positive. This leads to the opening of calcium channels, allowing calcium to enter the cell and cause the contraction of the filaments that trigger the release of insulin from stored vesicles. Glimepiride binds to both sulfonylurea receptor-1 and sulfony

When to interrupt dosage

The prescribed dose of Glimepiride is based on the diagnosed malady, including Type 2 Diabetes, Sulfonylurea Compounds and Diet. The dosage also varies as per the method of distribution (e.g. Tablet or Oral) laid out in the table beneath.
Condition
Dosage
Administration
inadequate response to monotherapy
, 1.0 mg, 4.0 mg, 2.0 mg, 3.0 mg, 6.0 mg, 8.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Sulfonylurea Compounds
, 1.0 mg, 4.0 mg, 2.0 mg, 3.0 mg, 6.0 mg, 8.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Type 2 Diabetes
, 1.0 mg, 4.0 mg, 2.0 mg, 3.0 mg, 6.0 mg, 8.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Diet
, 1.0 mg, 4.0 mg, 2.0 mg, 3.0 mg, 6.0 mg, 8.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Physical Activity
, 1.0 mg, 4.0 mg, 2.0 mg, 3.0 mg, 6.0 mg, 8.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Inadequate Glycaemic Control
, 1.0 mg, 4.0 mg, 2.0 mg, 3.0 mg, 6.0 mg, 8.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Inadequate Glucose Control
, 1.0 mg, 4.0 mg, 2.0 mg, 3.0 mg, 6.0 mg, 8.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

Glimepiride Contraindications
Condition
Risk Level
Notes
Type 1 Diabetes
Do Not Combine
allergic reaction to sulfonamide derivatives
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
There are 20 known major drug interactions with Glimepiride.
Common Glimepiride Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Minor
Glimepiride may increase the anticoagulant activities of (R)-warfarin.
(S)-Warfarin
Minor
Glimepiride may increase the anticoagulant activities of (S)-Warfarin.
Abrocitinib
Minor
The metabolism of Abrocitinib can be decreased when combined with Glimepiride.
Alosetron
Minor
The metabolism of Alosetron can be decreased when combined with Glimepiride.
Amprenavir
Minor
The metabolism of Amprenavir can be decreased when combined with Glimepiride.
Glimepiride Toxicity & Overdose RiskThe most toxic dose of glimepiride in rats is greater than 10000mg/kg. In an experiment with rats, doses of up to 5000 parts per million (ppm) did not cause cancer. However, when given to mice in high doses for 24 months, benign tumors in the pancreas were observed. Glimepiride did not cause any mutations in laboratory tests. In male and female rat studies, glimepiride had no impact on fertility. If someone takes too much glimepiride, they may experience severe low blood sugar with coma, seizures, or other neurological issues. This can be treated with gluc
image of a doctor in a lab doing drug, clinical research

Glimepiride Novel Uses: Which Conditions Have a Clinical Trial Featuring Glimepiride?

196 active trials are currently being conducted to assess the potential of Glimepiride in alleviating Type 2 Diabetes, Sulfonylurea Compounds and improving Physical Activity.
Condition
Clinical Trials
Trial Phases
Sulfonylurea Compounds
0 Actively Recruiting
inadequate response to monotherapy
0 Actively Recruiting
Inadequate Glycaemic Control
0 Actively Recruiting
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Inadequate Glucose Control
0 Actively Recruiting
Type 2 Diabetes
165 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Glimepiride Reviews: What are patients saying about Glimepiride?

5Patient Review
9/15/2015
Glimepiride for Type 2 Diabetes Mellitus
Janumet was giving me cancer risks, so my doctor switched me to this medication. It's been great so far, though I have to be careful of low blood sugar if I work harder than normal. I've dropped down to 1 mg a day now. The only downside is that metformin tears up my stomach pretty badly.
5Patient Review
9/8/2015
Glimepiride for Type 2 Diabetes Mellitus
I had a lot of trouble with Metformin and Onglyza, but adding glimepiride has really helped. My A1C levels have dropped from 7 to 5.0. Just be careful not to skip meals, as it can cause your blood sugar to drop too low.
5Patient Review
4/5/2016
Glimepiride for Type 2 Diabetes Mellitus
I'm an 65 year old male who had been taking 1000 mg of metformin for about 5 years. I started to get itching and hives, so my doctor prescribed glimepiride 2 mg. It has helped control my blood sugar level, but I feel tired all day now. Maybe I should talk to my doctor about adjusting the dosage.
5Patient Review
8/24/2018
Glimepiride for Type 2 Diabetes Mellitus
I've been really happy with this treatment, except for a few episodes of hypoglycemia that I experienced. These were resolved by taking glucose.
5Patient Review
2/16/2017
Glimepiride for Type 2 Diabetes Mellitus
Glimepiride 2mg was incredibly effective in getting my A1C down from a range of 150-180 to 100-120. I haven't experienced any serious side effects, just fatigue throughout the day.
5Patient Review
12/27/2016
Glimepiride for Type 2 Diabetes Mellitus
So far, Glimipirida has been the best drug I've taken for my condition. I take one milligram after breakfast and another one after dinner. This keeps my levels below 140 after a meal, and in the morning I wake up with 80.
4.7Patient Review
8/12/2015
Glimepiride for Type 2 Diabetes Mellitus
I started taking this medication at 2mg, but it actually caused my numbers to go up. By the time I reached 8mg, I was feeling really weak and tired, as well as experiencing chest pressure and other issues. I stopped taking the medicine after 30 days and saw some improvement, but then went back down to 2mg and still felt no relief. So today I stopped taking it altogether.
4.3Patient Review
12/4/2017
Glimepiride for Type 2 Diabetes Mellitus
I've been a Type 2 Diabetic for about 10 years now, and was managing my blood glucose (BG) levels with Metformin and diet. However, this year my numbers shot up into the 200s, so my doctor put me on Glimepiride. So far it's been effective in bringing my numbers back down into the 120s range. I'm hoping that my next A1C will reflect these lower levels.
4Patient Review
3/16/2016
Glimepiride for Type 2 Diabetes Mellitus
This has been really great - my A1C was 8.4 and in six months, it's dropped to 7.1 without any negative side effects that I've noticed.
3.7Patient Review
4/13/2020
Glimepiride for Type 2 Diabetes Mellitus
This treatment helped me regulate my blood sugar levels perfectly, but after a few months of taking it I developed severe diarrhea. It was so bad that I could hardly finish a meal before needing to use the bathroom.
3.3Patient Review
7/29/2016
Glimepiride for Type 2 Diabetes Mellitus
I took this medication for eleven months in order to lower my A1c levels. However, I constantly experienced gastric reactions and became dangerously constipated. My liver counts also rose to a dangerous level; if I had not participate in my company's health fair, I would never have known. So, if you're feeling tired all the time, make sure to ask your doctor to check your liver function.
2.3Patient Review
11/1/2015
Glimepiride for Type 2 Diabetes Mellitus
Glimepiride was working well for me, but my new doctor switched me to Metformin. Unfortunately, while my A1C dropped with Glimepiride, it rose significantly with Metformin. I also experienced terrible dizzy spells and nausea. So I'm back on Glimepiride now!
2.3Patient Review
7/10/2015
Glimepiride for Type 2 Diabetes Mellitus
2.3Patient Review
1/17/2020
Glimepiride for Type 2 Diabetes Mellitus
I started seeing an increase in my weight.
2Patient Review
8/6/2015
Glimepiride for Type 2 Diabetes Mellitus
I was switched to a 4mg dose two days ago and have since seen my blood sugar levels rise significantly. I'm not sure why this is the case, as I've been eating relatively healthily.
2Patient Review
3/6/2019
Glimepiride for Type 2 Diabetes Mellitus
This product was really terrible for me. My sugar levels were constantly spiking and I felt awful while taking it. Nauseous, dizzy, sleepy, lightheaded, and unable to focus. Once I stopped taking it everything went back to normal.
1Patient Review
12/4/2016
Glimepiride for Type 2 Diabetes Mellitus
I'm extremely disappointed in this medication. It hasn't helped me even a little, and we've already increased the dosage. As someone with kidney disease, I have limited options for treatment, so this was really my last hope.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about glimepiride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What glimepiride is used for?

"Glimepiride treats high blood sugar by increasing the amount of insulin produced by the pancreas. It is most effective when used in combination with another oral medicine, such as metformin."

Answered by AI

Is glimepiride the same as metformin?

"The medicine Amaryl is effective in lowering blood sugar, but it may cause weight gain as a side effect. Glucophage is the first choice medicine to control blood sugar and lower the risk of death from diabetes, although some people may not be able to tolerate the stomach side effects."

Answered by AI

What are the side effects of taking glimepiride?

"Some symptoms of low blood sugar levels are trembling or shaking, feeling nervous or anxious, being irritable, sweating, feeling lightheaded or dizzy, having a headache, or having a fast heart rate or palpitations. Other symptoms may include feeling nauseous, feeling weak, or gaining weight inexplicably."

Answered by AI

What is the best time of day to take glimepiride?

"You will typically take glimepiride once a day. You should take this medicine with food. Most people take it in the morning with their breakfast. If you do not eat breakfast, be sure to take it with your first meal of the day."

Answered by AI

Clinical Trials for Glimepiride

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Glimepiride clinical trials? We made a collection of clinical trials featuring Glimepiride, we think they might fit your search criteria.Go to Trials
Image of University of British Columbia - Okanagan in Kelowna, Canada.

Estrogen and Testosterone for Gender Differences in Physiology

18 - 40
All Sexes
Kelowna, Canada
Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.
Waitlist Available
Has No Placebo
University of British Columbia - OkanaganPhilip Ainslie, PhD
Have you considered Glimepiride clinical trials? We made a collection of clinical trials featuring Glimepiride, we think they might fit your search criteria.Go to Trials
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Image of Jefferson Health New Jersey in Sewell, United States.

Continuous vs Finger-stick Glucose Monitoring for Type 2 Diabetes in Pregnancy

18+
Female
Sewell, NJ
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Recruiting
Has No Placebo
Jefferson Health New Jersey (+1 Sites)
Image of McMaster University in Hamilton, Canada.

Health Coaching for Type 2 Diabetes and Mental Health

18+
All Sexes
Hamilton, Canada
Managing both type 2 diabetes and mental health challenges can be difficult, and many people do not receive care that supports both. This study looks at how virtual health coaching and support from interdisciplinary care teams can help people better manage their health. The purpose of this study is to test the effectiveness of a virtual health coaching program for adults living with type 2 diabetes and mental health challenges compared to usual care. The Technology-Enabled Collaborative Care for type 2 Diabetes and Mental health (TECC-DM) program includes weekly coaching calls, support from an interdisciplinary care team, and online tools to aid self-management. The findings from this study will be used to help improve services for people who have type 2 diabetes and co-occurring mental health symptoms.
Waitlist Available
Has No Placebo
McMaster UniversityCarly Whitmore, RN PhD
Have you considered Glimepiride clinical trials? We made a collection of clinical trials featuring Glimepiride, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security